Kbp Biosciences

This study tested a new drug called KBP-5074 in 162 people with moderate-to-severe chronic kidney disease whose blood pressure was still high despite treatment. Participants took either a low or high dose of the drug or a placebo daily for 84 days. The main goal was to see if the…

This early-stage study tested a single dose of the experimental drug KBP-5074 in 11 people with severe chronic kidney disease, including some on dialysis. The main goal was to check safety and how the drug moves through the body. No treatment benefits were measured; the study onl…

This early-stage study tested the safety and tolerability of a new drug called KBP-5074 in 26 adults, including healthy volunteers and those with mild to moderate kidney impairment. Researchers measured how the drug moves through the body and its effects on blood pressure and pot…

This early-stage study tested the safety and how the body processes different doses of KBP-5074 in 46 healthy adults. Researchers also looked at how food affects drug levels. The results will help choose the right doses for future studies in patients with kidney disease and high …

This early-stage study compared two versions (tablet vs capsule) of the experimental drug KBP-5074 in 20 healthy adults. The goal was to see how the body absorbs each form and whether they work similarly. Results will help choose the right dose for future studies.

This early-stage study looked at how a single dose of the experimental drug KBP-5074 is absorbed, broken down, and eliminated in 7 healthy men. Researchers measured radioactivity in blood, urine, and feces to understand the drug's path. The goal was not to treat any disease, but …

This early-stage study looked at how two common drugs—itraconazole (a fungal treatment) and rifampin (an antibiotic)—change the way the body processes KBP-5074, a potential medicine for high blood pressure or kidney disease. Twenty-four healthy adults took a single dose of KBP-50…

This early-stage study looked at how the drug KBP-5074 behaves in people with moderate liver impairment compared to healthy volunteers. Twelve adults received a single dose, and researchers monitored safety and drug levels in the blood. The goal was to see if liver problems chang…